Patents by Inventor Marc Capet

Marc Capet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BENZIMIDAZOLE DERIVATIVES AS DUAL HISTAMINE H1 AND HISTAMINE H4 RECEPTOR LIGANDS
    Publication number: 20220281839
    Abstract: The present application concerns novel benzimidazole enantiomeric derivatives, their process of preparation and their therapeutical uses as dual H1 and H4 receptor ligands.
    Type: Application
    Filed: February 10, 2022
    Publication date: September 8, 2022
    Inventors: Isabelle BERREBI-BERTRAND, Xavier BILLOT, Thierry CALMELS, Marc CAPET, Stéphane KRIEF, Olivier LABEEUW, Jeanne-Marie LECOMTE, Nicolas LEVOIN, Xavier LIGNEAU, Philippe ROBERT, Jean-Charles SCHWARTZ
  • Benzimidazole derivatives as dual histamine H1 and histamine H4 receptor ligands
    Patent number: 11306069
    Abstract: Novel benzimidazole enantiomeric derivatives, their process of preparation and their therapeutical uses as dual H1 and H4 receptor ligands are disclosed.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: April 19, 2022
    Assignee: BIOPROJET
    Inventors: Isabelle Berrebi-Bertrand, Xavier Billot, Thierry Calmels, Marc Capet, Stéphane Krief, Olivier Labeeuw, Jeanne-Marie Lecomte, Nicolas Levoin, Xavier Ligneau, Philippe Robert, Jean-Charles Schwartz
  • Therapeutical use of H3-ligands
    Patent number: 11179329
    Abstract: The present invention concerns new therapeutical uses, including low dosage administration of the highly potent H3-ligand: (3S)-4-{4-[3-(3-methylpiperidin-1-yl)propoxy]phenyl}pyridine 1-oxide.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: November 23, 2021
    Assignee: BIOPROJET PHARMA
    Inventors: Jeanne-Marie Lecomte, Jean-Charles Schwartz, Olivier Labeeuw, Marc Capet
  • Tetrahydrate of H3 ligand, its process of preparation and pharmaceutical compositions comprising the same
    Patent number: 11078183
    Abstract: The present invention concerns the tetrahydrate form of the compound: (3S)-4-{4-[3-(3-methylpiperidin-1-yl)propoxy]phenyl}pyridine 1-oxide, dihydrochloride, its process of preparation and therapeutical uses thereof.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: August 3, 2021
    Assignee: BIOPROJET
    Inventors: Marc Capet, Jeanne-Marie Lecomte, Jean-Charles Schwartz
  • NEW THERAPEUTICAL USE OF H3-LIGANDS
    Publication number: 20200093738
    Abstract: The present invention concerns new therapeutical uses, including low dosage administration of the highly potent H3-ligand: (3S)-4-{4-[3-(3-methylpiperidin-1-yl)propoxy]phenyl}pyridine 1-oxide.
    Type: Application
    Filed: March 21, 2018
    Publication date: March 26, 2020
    Applicant: BIOPROJET Pharma
    Inventors: Jeanne-Marie LECOMTE, Jean-Charles SCHWARTZ, Oliver LABEEUW, Marc CAPET
  • TETRAHYDRATE OF H3 LIGAND, ITS PROCESS OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
    Publication number: 20200024256
    Abstract: The present invention concerns the tetrahydrate form of the compound: (3S)-4-{4-[3-(3 -methylpiperidin-1-yl)propoxy]phenyl}pyridine 1-oxide, dihydrochloride, its process of preparation and therapeutical uses thereof.
    Type: Application
    Filed: March 20, 2018
    Publication date: January 23, 2020
    Applicant: BIOPROJET Pharma
    Inventors: Marc CAPET, Jeanne-Marie LECOMTE, Jean-Charles SCHWARTZ
  • BENZIMIDAZOLE DERIVATIVES AS DUAL HISTAMINE H1 AND HISTAMINE H4 RECEPTOR LIGANDS
    Publication number: 20190144421
    Abstract: Novel benzimidazole enantiomeric derivatives, their process of preparation and their therapeutical uses as dual H1 and H4 receptor ligands are disclosed.
    Type: Application
    Filed: November 15, 2018
    Publication date: May 16, 2019
    Inventors: Isabelle BERREBI-BERTRAND, Xavier BILLOT, Thierry CALMELS, Marc CAPET, Stéphane KRIEF, Olivier LABEEUW, Jeanne-Marie LECOMTE, Nicolas LEVOIN, Xavier LIGNEAU, Philippe ROBERT, Jean-Charles SCHWARTZ
  • Piperidinyl monocarboxylic acids as S1P1 receptor agonists
    Patent number: 9266867
    Abstract: The present invention relates to novel compounds acting as agonists at S1P (sphingosine-1-phosphate) receptors, compositions containing these compounds, use of these compounds in medicine and their process of preparation.
    Type: Grant
    Filed: April 10, 2012
    Date of Patent: February 23, 2016
    Assignees: BIOPROJET, SUN PHARMA ADVANCED RESEARCH COMPANY LTD
    Inventors: Marc Capet, Isabelle Berrebi-Bertrand, Philippe Robert, Jean-Charles Schwartz, Jeanne-Marie Lecomte, Rajamannar Thennati, Ranjan Kumar Pal, Biswajit Samanta, Muthukumaran Natarajan Pillai, Japan Nitinkumar Desai, Dijixa Chandubhai Rana, Kaushik Dhanjubhai Prajapati, Sandeep Pankajbhai Pathak, Bhavesh M. Panchal, Jayraj D. Aradhye
  • 6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azepines derivatives as histamine H4 receptor ligands
    Patent number: 9255101
    Abstract: The present patent application concerns new ligands of the H4-receptor, their process of preparation and their therapeutic use.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: February 9, 2016
    Assignee: BIOPROJET
    Inventors: Isabelle Berrebi-Bertrand, Xavier Billot, Thierry Calmels, Marc Capet, Stéphane Krief, Olivier Labeeuw, Jeanne-Marie Lecomte, Nicolas Levoin, Xavier Ligneau, Philippe Robert, Jean-Charles Schwartz
  • (Aza)benzhydryl ether derivatives, their process of preparation and their use as H4-receptor ligands for therapeutical applications
    Patent number: 9242959
    Abstract: The present invention concerns novel (aza)benzhydryl ether derivatives which exhibit H4-receptor binding activity. The present invention also concerns their process of preparation and their therapeutical uses.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: January 26, 2016
    Assignee: BIOPROJET
    Inventors: Isabelle Berrebi-Bertrand, Xavier Billot, Thierry Calmels, Marc Capet, Stéphane Krief, Olivier Labeeuw, Jeanne-Marie Lecomte, Nicolas Levoin, Xavier Ligneau, Philippe Robert, Jean-Charles Schwartz
  • ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF
    Publication number: 20150164894
    Abstract: Novel vinylazacycloalkane compounds of Formula (I) are disclosed. The compounds are ligands of various nAChRs. The compounds and their pharmaceutically acceptable salts can be used to prepare pharmaceutical compositions and/or medicaments intended to prevent or treat disorders associated with dysfunction of nAChRs, especially within the central nervous system or the gastrointestinal system. Examples of types of disorders that can be treated include neurodegenerative disorders, including central nervous system disorders such as Alzheimer's disease, cognitive disorders, motor disorders such as Parkinson's disease, drug addiction, behavioral disorders and inflammatory disorders within the gastrointestinal system. The compounds can also serve as analgesics in the treatment of acute, chronic or recurrent pain.
    Type: Application
    Filed: February 24, 2015
    Publication date: June 18, 2015
    Inventors: Jeffrey Daniel Schmitt, Gary Maurice Dull, Arielle Genevois-Borella, Marc Capet, Michel Cheve, Craig Harrison Miller
  • Benzazole derivatives as histamine H4 receptor ligands
    Patent number: 9029357
    Abstract: The present patent application concerns new ligands of the H4-receptor, their process of preparation and their therapeutic use.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: May 12, 2015
    Assignee: Bioprojet
    Inventors: Isabelle Berrebi-Bertrand, Xavier Billot, Thierry Calmels, Marc Capet, Denis Danvy, Stéphane Krief, Olivier Labeeuw, Jeanne-Marie Lecomte, Nicolas Levoin, Xavier Ligneau, Philippe Robert, Jean-Charles Schwartz
  • Benzazole Derivatives as Histamine H4 Receptor Ligands
    Publication number: 20150004181
    Abstract: The present patent application concerns new ligands of the H4-receptor, their process of preparation and their therapeutic use.
    Type: Application
    Filed: June 27, 2014
    Publication date: January 1, 2015
    Inventors: Isabelle BERREBI-BERTRAND, Xavier BILLOT, Thierry CALMELS, Marc CAPET, Denis DANVY, Stéphane KRIEF, Olivier LABEEUW, Jeanne-Marie LECOMTE, Nicolas LEVOIN, Xavier LIGNEAU, Philippe ROBERT, Jean-Charles SCHWARTZ
  • Dicarboxylic acid derivatives as S1P1 receptor agonists
    Patent number: 8809539
    Abstract: The present invention relates to new compounds of formula (I) possessing agonistic activity at sphingosine-1-phosphate (S1P) receptors, their process of preparation and their use as immunosuppressive agents. The invention is also directed to pharmaceutical compositions containing these compounds and use of these compounds for treatment/prevention of immune mediated diseases and conditions or inflammatory diseases and conditions.
    Type: Grant
    Filed: June 16, 2008
    Date of Patent: August 19, 2014
    Assignees: Bioprojet, Sun Pharma Advanced Research Company Ltd
    Inventors: Marc Capet, Nicolas Levoin, Isabelle Berrebi-Bertrand, Philippe Robert, Jean-Charles Schwartz, Jeanne-Marie Lecomte, Jayraj Dilipbhai Aradhye, Muthukumaran Natarajan Pillai, Bhavesh Mohanbhai Panchal, Jignesh Kantilal Jivani, Biswajit Samanta, Ranjan Kumar Pal, Rajamannar Thennati
  • Benzazole derivatives as histamine H4 receptor ligands
    Patent number: 8802664
    Abstract: The present patent application concerns new ligands of the H4-receptor of formula (I), their process of preparation and their therapeutic use.
    Type: Grant
    Filed: September 27, 2011
    Date of Patent: August 12, 2014
    Assignee: Bioproject
    Inventors: Isabelle Berrebi-Bertrand, Xavier Billot, Thierry Calmels, Marc Capet, Denis Danvy, Stephane Krief, Olivier Labeeuw, Jeanne-Marie Lecomte, Nicolas Levoin, Xavier Ligneau, Philippe Robert, Jean-Charles Schwartz
  • Carbonylated (aza) cyclohexanes as dopamine Dreceptor ligands
    Patent number: 8802678
    Abstract: The invention relates to compounds of the general formula (I): to the process for preparing them, and to the use thereof as a therapeutic agent.
    Type: Grant
    Filed: June 21, 2007
    Date of Patent: August 12, 2014
    Assignee: Bioprojet
    Inventors: Marc Capet, Denis Danvy, Nicolas Levoin, Isabelle Berrebi-Bertrand, Thierry Calmels, Philippe Robert, Jeanne-Marie Lecomte, Jean-Charles Schwartz, Xavier Ligneau
  • ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF
    Publication number: 20140107164
    Abstract: Novel vinylazacycloalkane compounds of Formula (I) are disclosed. The compounds are ligands of various nAChRs. The compounds and their pharmaceutically acceptable salts can be used to prepare pharmaceutical compositions and/or medicaments intended to prevent or treat disorders associated with dysfunction of nAChRs, especially within the central nervous system or the gastrointestinal system. Examples of types of disorders that can be treated include neurodegenerative disorders, including central nervous system disorders such as Alzheimer's disease, cognitive disorders, motor disorders such as Parkinson's disease, drug addiction, behavioral disorders and inflammatory disorders within the gastrointestinal system. The compounds can also serve as analgesics in the treatment of acute, chronic or recurrent pain.
    Type: Application
    Filed: December 17, 2013
    Publication date: April 17, 2014
    Applicant: Targacept, Inc.
    Inventors: Jeffrey Daniel Schmitt, Gary Maurice Dull, Arielle Genevois-Borella, Marc Capet, Michel Cheve, Craig Harrison Miller
  • NOVEL PIPERIDINYL MONOCARBOXYLIC ACIDS AS S1P1 RECEPTOR AGONISTS
    Publication number: 20140099316
    Abstract: The present invention relates to novel compounds acting as agonists at S1P (sphingosine-1-phosphate) receptors, compositions containing these compounds, use of these compounds in medicine and their process of preparation.
    Type: Application
    Filed: April 10, 2012
    Publication date: April 10, 2014
    Applicants: SUN PHARMA ADVANCED RESEARCH COMPANY LTD., BIOPROJET
    Inventors: Marc Capet, Isabelle Berrebi-Bertrand, Philippe Robert, Jean-Charles Schwartz, Jeanne-Marie Lecomte, Rajamannar Thennati, Ranjan Kumar Pal, Biswajit Samanta, Muthukumaran Natarajan Pillai, Japan Nitinkumar Desai, Dijixa Chandubhai Rana, Kaushik Dhanjubhai Prajapati, Sandeep Pankajbhai Pathak, Bhavesh M. Panchal, Jayraj D. Aradhye
  • Arylvinylazacycloalkane compounds and methods of preparation and use thereof
    Patent number: 8633222
    Abstract: Novel vinylazacycloalkane compounds of Formula (I) are disclosed. The compounds are ligands of various nAChRs. The compounds and their pharmaceutically acceptable salts can be used to prepare pharmaceutical compositions and/or medicaments intended to prevent or treat disorders associated with dysfunction of nAChRs, especially within the central nervous system or the gastrointestinal system. Examples of types of disorders that can be treated include neurodegenerative disorders, including central nervous system disorders such as Alzheimer's disease, cognitive disorders, motor disorders such as Parkinson's disease, drug addiction, behavioral disorders and inflammatory disorders within the gastrointestinal system. The compounds can also serve as analgesics in the treatment of acute, chronic or recurrent pain.
    Type: Grant
    Filed: February 24, 2011
    Date of Patent: January 21, 2014
    Assignee: Targacept, Inc.
    Inventors: Jeffrey Daniel Schmitt, Gary Maurice Dull, Arielle Genevois-Borella, Marc Capet, Michel Cheve, Craig Harrison Miller
  • New 6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azepines derivatives as histamine H4 receptor ligands
    Publication number: 20130324506
    Abstract: The present patent application concerns new ligands of the H4-receptor, their process of preparation and their therapeutic use.
    Type: Application
    Filed: June 5, 2013
    Publication date: December 5, 2013
    Inventors: Isabelle BERREBI-BERTRAND, Xavier BILLOT, Thierry CALMELS, Marc CAPET, Stéphane KRIEF, Olivier LABEEUW, Jeanne-Marie LECOMTE, Nicolas LEVOIN, Xavier LIGNEAU